IL-31 is a protein that drives itch and plays a role in inflammation and skin barrier dysfunction in both AD and prurigo nodularis and fibrosis in prurigo nodularis, the company states.

Nemluvio’s approved indications include atopic dermatitis in patients aged 12 years and older and prurigo nodularis in adults. The approvals are supported by two phase 3 clinical trial programs.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for nemolizumab (Nemluvio, Galderma) to treat moderate to severe prurigo nodularis in adults and ...

The European Commission (EC) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The drug has been authorised for use in atopic dermatitis patients ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nemolizumab (brand name Nemluvio) for the treatment of two skins conditions – moderate to severe prurigo ...

Atopic dermatitis (AD) and prurigo nodularis (PN) disproportionately impact Black and Brown communities, yet these conditions remain underrepresented in mainstream dermatology. Many individuals ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two skin conditions The newly approved medicine will treat moderate to severe ...

Elon Musk Steps Up Efforts to Cull Federal Work Force Mr. Musk said federal workers must summarize their accomplishments for the week or be forced to leave, borrowing a tactic he used at his ...

What Germans decide in national elections that are likely to produce a new chancellor will be of critical importance as Europe re-evaluates relations with the Trump administration. By ...

Editor’s note: Sign up for Unlocking the World, CNN Travel’s weekly newsletter. Get news about destinations, plus the latest in aviation, food and drink, and where to stay. New Zealand’s new ...